Lost Money on Vanda Pharmaceuticals Inc. (VNDA)? Contact Levi & Korsinsky About Fraud Investigation

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential violations of federal securities laws following a significant stock price drop due to FDA's decision on its drug application for HETLIOZ® [1][2]. Group 1: Company News - Vanda Pharmaceuticals announced on January 8, 2026, that the FDA's CDER concluded that the supplemental New Drug Application (sNDA) for HETLIOZ® for treating jet lag disorder cannot be approved in its current form [2]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the evidence was insufficient for effectiveness in treating jet lag disorder, citing that the trial protocols did not adequately simulate actual jet travel conditions [2]. - Following the FDA's announcement, Vanda's stock price fell over 14% on January 8, 2026 [2]. Group 2: Legal and Investigation - Levi & Korsinsky has commenced an investigation into Vanda Pharmaceuticals regarding potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].